New Ray Medicine International Holding Limited (HKG:6108)

HKG:6108 Financials Overview

Financials in millions HKD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	199.09	130.37	93.95	50.15	89.77	335.38
Revenue Growth	52.71%	38.78%	87.31%	-44.13%	-73.23%	151.76%
Gross Profit Gross Profit Growth	22.36	16.15	-1.62	11.34	-29.18	28.49
Operating Income Operating Income Growth	-13	-16.3	-37.94	-21.42	-73.42	-7.08
Net Income Net Income Growth	-16.18	-20.07	-31.01	-22.17	-77.95	-2.82
Earnings Per Share EPS Growth	-0.09	-0.12	-0.19	-0.13	-0.47	-0.02
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Distribution and Trading of Pharmaceutical Products Distribution and Trading of Pharmaceutical Products Growth	197.49	127.93	88.71	42.85	83.75	329.62
Provision of Marketing and Promotion Services of Drugs Provision of Marketing and Promotion Services of Drugs Growth	1.61	2.44	5.24	7.3	6.02	5.76
Total Total Growth	199.09	130.37	93.95	50.15	89.77	335.38

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	73.58	37.42	64.26	103.95	154.41	150.15
Total Debt Total Debt Growth	2.12	2.47	3.55	0.29	1.28	12.84
Net Cash (Debt) Net Cash Growth	71.46	34.96	60.71	103.67	153.14	137.31
Net Cash Growth	104.43%	-42.42%	-41.44%	-32.30%	11.52%	116.73%
Net Cash Per Share Net Cash Per Share Growth	0.39	0.21	0.36	0.62	0.92	0.82

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-	-54.14	-4.77	-45.41	-0.32	-58.39
Capital Expenditures CapEx Growth	-	-0.31	-0.62	-0.04	-8.7	-0.06
Free Cash Flow Free Cash Flow Growth	-	-54.45	-5.39	-45.45	-9.02	-58.45
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	11.23%	12.39%	-1.73%	22.61%	-32.51%	8.49%
Operating Margin	-6.53%	-12.50%	-40.38%	-42.71%	-81.78%	-2.11%
Pretax Margin	-8.06%	-15.30%	-34.13%	-44.55%	-89.43%	-1.08%
Profit Margin	-8.13%	-15.39%	-33.01%	-44.20%	-86.83%	-0.84%
FCF Margin	-	-41.77%	-5.73%	-90.62%	-10.04%	-17.43%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 13, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Forward PE	-	18.72	18.72	18.72	18.72	18.72
PS Ratio	0.22	0.42	0.80	1.67	1.77	2.12

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 13, 2026

Data Sources Report a data error